Compare MFA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | KURA |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | 260 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | MFA | KURA |
|---|---|---|
| Price | $9.42 | $9.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $11.05 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $10.02 | $106.37 |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $8.78 | $5.45 |
| 52 Week High | $10.57 | $12.49 |
| Indicator | MFA | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 50.05 |
| Support Level | $9.38 | $8.95 |
| Resistance Level | $10.26 | $9.82 |
| Average True Range (ATR) | 0.22 | 0.43 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 9.55 | 45.89 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.